Soleno Therapeutics Investors Face Class Action Lawsuit Over Significant Losses

In a significant turn of events, Soleno Therapeutics Inc. is now entangled in a class action lawsuit due to allegations of misleading investors about the safety and commercial viability of its primary product, DCCR (diazoxide choline extended-release tablets). This case comes to light as Robbins Geller Rudman & Dowd LLP, a law firm with a robust history in investor lawsuits, encourages affected investors to emerge for the lead plaintiff role in this matter.

The Class Action Overview

The class action was initiated on March 16, 2026, and targets individuals who acquired Soleno's common stock between March 26, 2025, and November 4, 2025. The lawsuit claims that top executives of Soleno failed to disclose critical safety issues related to DCCR, particularly in relation to its administration for treating hyperphagia in patients suffering from Prader-Willi syndrome. Investors have until May 5, 2026, to express interest in leading this case, which is captioned as City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, Inc.

This class action raises serious questions about the ethical practices in biotech and pharmaceuticals, particularly regarding how companies handle clinical trial results and communicate risk to their investors.

Allegations Against Soleno

The allegations against Soleno include:
1. Underreporting Safety Concerns: Investors allege that Soleno downplayed and misrepresented significant safety concerns during DCCR’s clinical trials, particularly around the risk of excess fluid retention among patients involved in the studies.

2. Deceptive Marketing Claims: As a result of these disclosures, the lawsuit argues that DCCR posed more substantial safety risks than what the company had presented to the market.

3. Commercial Viability Issues: Due to the alleged misrepresentation, DCCR had a lower potential for commercial success, with concerns regarding patient adoption rates, potential regulatory challenges, and reputational harm surfacing post-launch.

The Impact on Soleno's Stock

The ramifications for Soleno’s stock have been profound. Following critical reports published by Scorpion Capital on August 15, 2025, the company's stock saw a nearly 12% drop within two trading days. Separately, a tragic event reported on September 10, 2025, after a patient died post-DCCR administration led to a substantial share price plummet of about 19%. In the culmination of these events, on November 4, 2025, a public disclosures of disrupted commercialization strategies caused the stock to decline by approximately 27% in just a couple of days.

Investor Participation and Legal Process

Investors who experienced significant losses during the class period can participate in the class action process. They may seek appointment as the lead plaintiff based on their financial stake and the outcomes pursued within the suit's framework. Lead plaintiffs have the authority to choose a law firm to represent their interests, although participation in the suit does not require being a lead plaintiff.

Robbins Geller, as the prosecuting law firm, offers an experienced team that has successfully managed numerous securities fraud cases, safeguarding investor rights and interests.

Understanding the nuances of this lawsuit is crucial for any investor impacted by the rise and fall of Soleno Therapeutics' stock. If you believe you have a stake in this case, it is paramount that you take action before the deadline to potentially lead the charge against alleged corporate misconduct.

Conclusion

The ongoing case against Soleno Therapeutics serves as a reminder of the risks associated with investing in biopharmaceutical stocks and the importance of corporate transparency in clinical trials. As this class action unfolds, affected investors are urged to stay informed and consider their options in this critical juncture of legal proceedings.